Navigation Links
Hospira Reports First-Quarter 2012 Results
Date:5/1/2012

LAKE FOREST, Ill., May 1, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2012. Net sales for the quarter were $966 million and adjusted* diluted earnings per share were $0.47. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)

"Hospira delivered first-quarter results in line with our expectations, which reflects a difficult year-over-year comparison and the impact of our quality improvement initiatives," said F. Michael Ball, chief executive officer. "Going forward, we remain firmly focused on advancing our remediation efforts and, at the same time, expanding our global footprint and capacity to capitalize on our growth opportunities. We believe these initiatives will position Hospira with an even stronger competitive advantage, creating sustainable, long-term shareholder value."

First-Quarter 2012 ResultsThe following table highlights selected financial results for the first quarter of 2012 compared to the same period in 2011:In $ millions,

except per share

amounts

GAAP

Three Months Ended

March 31, Adjusted*

Three Months Ended

March 31,2012

2011

%

Change

2012

2011

%

ChangeNet Sales

$965.9

$1,002.3

(3.6)%

n/a

n/a

n/aGross Profit (Net Sales less

Cost of Products Sold)

$300.0

$399.1

(24.8)%

$357.5

$424.3

(15.7)%Income from Operations

$46.7

$163.8

(71.5)%

$104.2

$203.4

(48.8)%Diluted Earnings per Share

$0.24

$0.88

(72.7)%

$0.47

$0.93

(49.5)%Statistics (as a % of Net
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Joins the Generic Pharmaceutical Association
3. Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Months Supply of New Product Immediately and on Track to Ensure Sustainable Supply
4. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
5. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
6. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
7. Hospira Reports Third-Quarter 2011 Results
8. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
9. Hospira to Host Conference Call for Third-Quarter 2011 Results
10. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
11. Hospira to Host 2011 Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Makindus, Inc. a specialty pharmaceutical development company ... Agency (EMA) has granted orphan drug designation for their ... "We are extremely pleased to now have ... in place for Europe . This ... the United States for which orphan designation ...
(Date:5/4/2015)... DENVER , May 4, 2015  By ... now possible to distinguish between two very different ... to Theodore Henderson , MD, PhD., a ... diagnosing complex cases, this study can ... differences, and therefore treatment options, for Post-Traumatic Stress ...
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
Breaking Medicine Technology:European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
(Date:5/4/2015)... (PRWEB) May 04, 2015 Johnson & Wales ... million engineering and science academic center on Wednesday, April 22. ... ground for land made available by the re-alignment of Interstate-195. ... corner of Friendship and Chestnut streets in Providence, is scheduled ... on a parcel of land the university purchased in 2012. ...
(Date:5/4/2015)... Healthcare Solutions is proud to be a sponsor at ... in Baltimore, MD from May 11 – 13, 2015. ... opportunity for clients to gather to network, attend educational ... to sponsoring the event, TROY Healthcare Solutions will be ... can stop by the TROY booth and see sample ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Baptist ... Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold ... Stroke Honor Roll. The award recognizes the hospital’s ... receive the most appropriate treatment according to nationally ... evidence. , To receive the Gold Plus Quality ...
(Date:5/4/2015)... METTLER TOLEDO has announced an upcoming ... in a GXP Regulated Laboratory ", featuring independent ... will be presented on May 27, 2015 at ... a critical component of pharmaceutical product quality and ... recent years an increasing number of inspections have ...
Breaking Medicine News(10 mins):Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2
... , THURSDAY, March 3 (HealthDay News) -- More than ... a night, which affects their concentration and general health, ... work performance and the ability to drive safely, found ... Prevention (CDC), which published two sleep studies March 4 ...
... 3 (HealthDay News) -- An analysis of breast tissue may ... a new study reports. Researchers analyzed what they describe ... found that the way collagen fibers -- the main component ... patient,s diagnosis and help determine treatment. Collagen not only ...
... The burning, tingling pain of neuropathy may affect feet ... of nerve cells that supply the extremities age and ... these areas, Johns Hopkins scientists suggest in a new ... to fight neuropathy, a condition that often accompanies other ...
... (HealthDay News) -- Bunions, a common but painful deformity of the ... a new study has found. And the more severe the ... other parts of the body, leading to declines in both general ... is a bump that develops on the side of the big ...
... The American Thoracic Society has released a new report ... immunodeficiency virus (HIV)-associated pulmonary disease. The report examines the ... areas where combination antiretroviral therapies (ART) are available, as ... areas of the world where ART use is limited. ...
... tuberculosis (TB) bacteria develop multi-drug tolerance point to ways TB ... be published April 1 in the journal Cell . ... for drug tolerance that is induced in the TB bacteria ... requires a complex, long-term curative regimen of at least six ...
Cached Medicine News:Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 3Health News:ATS issues report on emerging issues in HIV-associated pulmonary disease 2Health News:ATS issues report on emerging issues in HIV-associated pulmonary disease 3Health News:New findings on drug tolerance in TB suggest ideas for shorter cures 2Health News:New findings on drug tolerance in TB suggest ideas for shorter cures 3
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Conducting disposable filter-tips....
300 L, Bulk Recommended for 250 and 300 L pipettes....
Medicine Products: